concurrent chemoradiation therapy-National Cancer Center, Korea-non-small cell lung cancer

This refers to a specific neoadjuvant treatment regimen developed and evaluated by the National Cancer Center, Korea, for patients with biopsy-proven N2 stage IIIA non-small cell lung cancer (NSCLC). The regimen is a trimodal approach consisting of concurrent chemoradiation therapy (CCRT) followed by surgery. The pharmaceutical component of the CCRT involves the administration of the chemotherapy agents paclitaxel and cisplatin concurrently with thoracic radiation. In the specific Phase II trial context (NCT00433511), the regimen utilized paclitaxel (50 mg/m²) and cisplatin (20 mg/m²) on days 1 and 8 every 3 weeks for two cycles preoperatively, alongside a total radiation dose of 4500 cGy. Paclitaxel acts as a microtubule stabilizer to inhibit cell division, while cisplatin is a platinum-based agent that induces DNA cross-linking; together, they serve as radiosensitizers to enhance the efficacy of ionizing radiation in achieving locoregional tumor control and improving surgical resectability.

Other names

CCRTpaclitaxel + cisplatin + radiation therapypreoperative concurrent chemoradiotherapy